Enoxaparin PK 10169; Enoxaparin sodium; Lovenox|cas:679809-58-6|西域试剂

Enoxaparin PK 10169; Enoxaparin sodium; Lovenox

产品编号：Bellancom-109509| CAS NO：679809-58-6| 分子式：C₂₆H₄₂N₂O₃₇S₅| 分子量：1134.92788

依诺肝素（PK 10169），一种低分子量肝素（LMWH）衍生物。依诺肝素通过抗凝血酶III发挥抗凝活性，抗凝血酶Ⅲ是因子Xa和凝血酶IIa的内源性抑制剂。依诺肝素通过抗氧化和抗炎特性保护大鼠海马免受TBI（创伤性脑损伤）。依诺肝素可用于研究深静脉血栓形成（DVT）、肺栓塞、TBI和新冠肺炎。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-109509	￥720.00	杭州北京（现货）
Bellancom-109509	￥1150.00	杭州北京（现货）
Bellancom-109509	￥2200.00	杭州北京（现货）
Bellancom-109509	￥3400.00	杭州北京（现货）
Bellancom-109509	￥5250.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Enoxaparin PK 10169; Enoxaparin sodium; Lovenox

产品介绍

Enoxaparin (PK 10169) 是一种低分子肝素 (LMWH) 衍生物。Enoxaparin 通过抗凝血酶 III 发挥其抗凝血 (anticoagulant) 活性，抗凝血酶 III 是一种内源性 Xa 因子和凝血酶 IIa (thrombin IIa) 的抑制剂。Enoxaparin 可通过抗氧化 (antioxidant) 和抗炎 (anti-inflammatory) 作用保护大鼠海马区免受 TBI 损伤。Enoxaparin 可用于深静脉血栓形成 (DVT)、肺栓塞、外伤性脑损伤 (TBI) 和 COVID-19 的研究。

生物活性

Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19.

体外研究

Enoxaparin (0-70 µg/mL, 90 min) enhances AAT (alpha-1-antitrypsin) inhibition of both TMPRSS2 (Transmembrane Protease 2) activity and infection of hAEc (human airway epithelial cells) with HCoV-229E.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	HEK293T ^TMPRSS2 cells, hAEc
Concentration:	0, 8.8, 35, 70 µg/mL
Incubation Time:	90 min
Result:	Significantly inhibited TMPRSS2 activity at the 90 min incubation period at 35 and 70 µg/mL, enhanced AAT inhibition of TMPRSS2 activity, and augmented AAT inhibition of HCoV-229E infection of hAEc.

体内研究
(In Vivo)

Enoxaparin (1 mg/kg; SC; once every 6 h for 8 times) reduces oxidative damage, inflammation and astrocytosis following TBI (traumatic brain injury) in the rat.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Wistar rats (350-450 g, TBI-treated)
Dosage:	0 mg/kg, 1 mg/kg
Administration:	SC, once every 6 h, starting at 1 h, and finishing at 43 h after the TBI induction.
Result:	Significantly decreased the hippocampal TBARS and oxidized protein levels, COX-2 overexpression and reactive gliosis, but it did not influence the SOD and GSH-Px activities, pro-IL-1β and active caspase-3 overexpressions as well as neurodegeneration following TBI. Reduce oxidative damage, inflammation and astrocytosis following TBI in the rat.

体内研究

Enoxaparin (1 mg/kg; SC; once every 6 h for 8 times) reduces oxidative damage, inflammation and astrocytosis following TBI (traumatic brain injury) in the rat.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Wistar rats (350-450 g, TBI-treated)
Dosage:	0 mg/kg, 1 mg/kg
Administration:	SC, once every 6 h, starting at 1 h, and finishing at 43 h after the TBI induction.
Result:	Significantly decreased the hippocampal TBARS and oxidized protein levels, COX-2 overexpression and reactive gliosis, but it did not influence the SOD and GSH-Px activities, pro-IL-1β and active caspase-3 overexpressions as well as neurodegeneration following TBI. Reduce oxidative damage, inflammation and astrocytosis following TBI in the rat.

体内研究

Enoxaparin (1 mg/kg; SC; once every 6 h for 8 times) reduces oxidative damage, inflammation and astrocytosis following TBI (traumatic brain injury) in the rat.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Wistar rats (350-450 g, TBI-treated)
Dosage:	0 mg/kg, 1 mg/kg
Administration:	SC, once every 6 h, starting at 1 h, and finishing at 43 h after the TBI induction.
Result:	Significantly decreased the hippocampal TBARS and oxidized protein levels, COX-2 overexpression and reactive gliosis, but it did not influence the SOD and GSH-Px activities, pro-IL-1β and active caspase-3 overexpressions as well as neurodegeneration following TBI. Reduce oxidative damage, inflammation and astrocytosis following TBI in the rat.

性状

Solid

溶解性数据

In Vitro:

H₂O : ≥ 100 mg/mL

* "≥" means soluble, but saturation unknown.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献

. Bai X, et al. Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19. Sci Rep. 2022 Mar 25;12(1):5207. [Content Brief]

. Župan Ž, et al. Effects of enoxaparin in the rat hippocampus following traumatic brain injury. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1846-56. [Content Brief]

. Lee S, Gibson CM. Enoxaparin in acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007 May;5(3):387-99. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

Enoxaparin PK 10169; Enoxaparin sodium; Lovenox

Enoxaparin PK 10169; Enoxaparin sodium; Lovenox

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询